# US FDA rejects lung cancer drug from China

> US FDA rejects Chinese lung cancer drug after trial shows no life extension.
- Title: US FDA rejects lung cancer drug from China · The Straits Times
- Summary: US FDA rejects Chinese lung cancer drug after trial shows no life extension. US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso…
- Keywords: us food and drug administration, ivonescimab, akeso biopharma, summit therapeutics, lung cancer, clinical trial, statistically significant life extension, The Straits Times
- URL: https://shortify.news/The_Straits_Times/us-fda-rejects-lung-cancer-drug-from-china
- Source: The Straits Times — https://straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china
- Published: 2026-11-16T00:57:00+00:00
- Read time: 1 min
- Topics: us food and drug administration, ivonescimab, akeso biopharma, summit therapeutics, lung cancer, clinical trial, statistically significant life extension, news, world
## FDA rejection
US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma and licensed by Summit Therapeutics, after clinical trials failed to show statistically significant life extension.
## Drug development setback
Summit Therapeutics disclosed the FDA's decision on Nov 15, 2026, after buying US rights from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories.
## Market impact
The rejection weakens hopes that ivonescimab could rival Keytruda, though the drug is still being tested in other cancers such as colon, bladder and breast.
## Key takeaway

US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension.

---

Summary: Shortify — https://shortify.news/The_Straits_Times/us-fda-rejects-lung-cancer-drug-from-china
Reporting: The Straits Times — https://straitstimes.com/world/united-states/us-fda-rejects-closely-watched-lung-cancer-drug-from-china

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.